# US 2023/0058784 A1 · Circular rna compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058784 A1
- Document ID: US20230058784A1
- Status: Published application
- Kind: A1
- Application number: 17/503,208
- Filed: 2021-10-15
- Published: 2023-02-23
- Earliest claimed: 2019-12-04
- Assignees: Orna Therapeutics, Inc.
- Applicants: Orna Therapeutics, Inc.
- Inventors: Brian Goodman; Alexander Wesselhoeft; Allen Horhota; Junghoon Yang
- Web page: https://patentgrep.com/patent/US20230058784A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/0011: {Cancer antigens}
- A61K 39/001112: {CD19 or B4}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- A61K 48/0041: {the non-active part being polymeric}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- A61K 2039/5156: {expressing foreign proteins}
- C07K 2319/50: containing protease site
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/532: Closed or circular
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are circular RNA s and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.

## Claims

### Claim 1

An ionizable lipid of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein
each n is independently an integer from 2-15;
L1 and L3 are each independently —OC(O)—* or —C(O)O—*, wherein “*” indicates the attachment point to R1 or R3;
R1 and R3 are each independently a linear or branched C9-C20 alkyl or C9-C20 alkenyl, optionally substituted by one or more substituents selected from a group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkynyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; and
R2 comprises an optionally substituted five-membered heteroaryl selected from imidazolyl, pyrazolyl, or 1,2,4-triazolyl, wherein when R2 comprises imidazolyl, the imidazolyl is not fused with a pyrimidinyl ring.

### Claim 2 (depends on 1)

The ionizable lipid of claim 1, wherein R2 comprises an optionally substituted imidazole.

### Claim 3 (depends on 1)

The ionizable lipid of claim 1, wherein R2 is selected from a group consisting of:

### Claim 4 (depends on 1)

The ionizable lipid of claim 1, wherein the ionizable lipid is represented by Formula (1-1) or Formula (1-2):

### Claim 5 (depends on 1)

The ionizable lipid of claim 1, wherein R1 and R3 are each independently selected from the group consisting of:

### Claim 6 (depends on 1)

The ionizable lipid of claim 1, wherein R1 and R3 are the same.

### Claim 7 (depends on 1)

The ionizable lipid of claim 1, selected from the group consisting of:

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a transfer vehicle, wherein the transfer vehicle comprises the ionizable lipid of claim 1.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the transfer vehicle comprises a helper lipid and/or structural lipid.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the structural lipid binds to C1q, and/or promotes the binding of the transfer vehicle comprising said lipid to C1q compared to a control transfer vehicle lacking the structural lipid, and/or increases uptake of C1q-bound transfer vehicle into an immune cell compared to a control transfer vehicle lacking the structural lipid.

### Claim 11 (depends on 8)

The pharmaceutical composition of claim 8, wherein the transfer vehicle comprises a PEG-lipid.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the PEG-lipid is a modified PEG-lipid.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the modified PEG-lipid is selected from PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG-DSPE, PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, or a combination thereof.

### Claim 14 (depends on 8)

The pharmaceutical composition of claim 8, wherein the pharmaceutical composition further comprises a RNA polynucleotide.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, where the RNA polynucleotide is linear or circular.

### Claim 16

A lipid nanoparticle (LNP) comprising an ionizable lipid, a helper lipid, and a structural lipid, wherein the ionizable lipid is a compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein
each n is independently an integer from 2-15;
L1 and L3 are each independently —OC(O)—* or —C(O)O—*, wherein “*” indicates the attachment point to R1 or R3;
R1 and R3 are each independently a linear or branched C9-C20 alkyl or C9-C20 alkenyl, optionally substituted by one or more substituents selected from a group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkynyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; and
R2 comprises an optionally substituted five-membered heteroaryl selected from imidazolyl, pyrazolyl, or 1,2,4-triazolyl, wherein when R2 comprises imidazolyl, the imidazolyl is not fused with a pyrimidinyl ring.

### Claim 17 (depends on 16)

The LNP of claim 16, wherein R2 comprises an optionally substituted imidazole.

### Claim 18 (depends on 16)

The LNP of claim 16, wherein R2 is selected from a group consisting of:

### Claim 19 (depends on 16)

The LNP of claim 16, wherein R1 and R3 are each independently selected from the group consisting of:

### Claim 20 (depends on 16)

The LNP of claim 16, wherein R1 and R3 are the same.

### Claim 21 (depends on 16)

The LNP of claim 16, wherein the ionizable lipid is selected from the group consisting of:

### Claim 22 (depends on 16)

A pharmaceutical composition comprising: (1) a payload molecule; and (2) a LNP of claim 16.

### Claim 23 (depends on 22)

The pharmaceutical composition of claim 22, wherein the payload molecule comprises a RNA polynucleotide.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein the RNA polynucleotide is linear or circular.

### Claim 25 (depends on 16)

A method of delivering a therapeutic agent to a target cell, comprising administering a LNP of claim 16.

### Claim 26 (depends on 25)

The method of claim 25, wherein the therapeutic agent is a RNA polynucleotide.

### Claim 27 (depends on 26)

The method of claim 26, wherein the RNA polynucleotide is linear or circular.

### Claim 28 (depends on 27)

The method of claim 27, wherein the target cell is a eukaryotic cell.

### Claim 29 (depends on 28)

The method of claim 28, wherein the eukaryotic cell is a hepatocyte, epithelial cell, hematopoietic cell, epithelial cell, endothelial cell, lung cell, bone cell, stem cell, mesenchymal cell, neural cell, photoreceptor cells, retinal pigmented epithelial cells, secretory cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes and tumor cells, an NK cell, an NKT cell, a macrophage, or a neutrophil.
